25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Polycomb-Dependent Repression of the Potassium Channel-Encoding Gene KCNA5 Promotes Cancer Cell Survival Under Conditions of Stress

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Relapse after clinical remission remains a leading cause of cancer-associated death. Although the mechanisms of tumor relapse are complex, the ability of cancer cells to survive physiologic stress is a prerequisite for recurrence. Ewing sarcoma (ES) and neuroblastoma (NB) are aggressive cancers that frequently relapse after initial remission. In addition, both tumors over-express the polycomb group (PcG) proteins BMI-1 and EZH2, which contribute to tumorigenicity. We have discovered that ES and NB resist hypoxic stress-induced death and that survival depends on PcG function. Epigenetic repression of developmental programs is the most well established cancer-associated function of PcG proteins. However, we noted that voltage-gated potassium (Kv) channel genes are also targets of PcG regulation in stem cells. Given the role of potassium in regulating apoptosis, we reasoned that repression of Kv channel genes might play a role in cancer cell survival. Here, we describe our novel finding that PcG-dependent repression of the Kv1.5 channel gene, KCNA5, contributes to cancer cell survival under conditions of stress. We show that survival of cancer cells in stress is dependent upon suppression of Kv1.5 channel function. The KCNA5 promoter is marked in cancer cells with PcG-dependent chromatin repressive modifications that increase in hypoxia. Genetic and pharmacologic inhibition of BMI-1 and EZH2, respectively, restore KCNA5 expression, which sensitizes cells to stress-induced death. In addition, ectopic expression of the Kv1.5 channel induces apoptotic cell death under conditions of hypoxia. These findings identify a novel role for PcG proteins in promoting cancer cell survival via repression of KCNA5.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Identification of selective inhibitors of cancer stem cells by high-throughput screening.

          Screens for agents that specifically kill epithelial cancer stem cells (CSCs) have not been possible due to the rarity of these cells within tumor cell populations and their relative instability in culture. We describe here an approach to screening for agents with epithelial CSC-specific toxicity. We implemented this method in a chemical screen and discovered compounds showing selective toxicity for breast CSCs. One compound, salinomycin, reduces the proportion of CSCs by >100-fold relative to paclitaxel, a commonly used breast cancer chemotherapeutic drug. Treatment of mice with salinomycin inhibits mammary tumor growth in vivo and induces increased epithelial differentiation of tumor cells. In addition, global gene expression analyses show that salinomycin treatment results in the loss of expression of breast CSC genes previously identified by analyses of breast tissues isolated directly from patients. This study demonstrates the ability to identify agents with specific toxicity for epithelial CSCs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Calcium and cancer: targeting Ca2+ transport.

            Ca2+ is a ubiquitous cellular signal. Altered expression of specific Ca2+ channels and pumps are characterizing features of some cancers. The ability of Ca2+ to regulate both cell death and proliferation, combined with the potential for pharmacological modulation, offers the opportunity for a set of new drug targets in cancer. However, the ubiquity of the Ca2+ signal is often mistakenly presumed to thwart the specific therapeutic targeting of proteins that transport Ca2+. This Review presents evidence to the contrary and addresses the question: which Ca2+ channels and pumps should be targeted?
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

              The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a (potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials.
                Bookmark

                Author and article information

                Journal
                8711562
                6325
                Oncogene
                Oncogene
                Oncogene
                0950-9232
                1476-5594
                31 October 2014
                01 December 2014
                27 August 2015
                27 February 2016
                : 34
                : 35
                : 4591-4600
                Affiliations
                [a ]Department of Pharmacology, University of Michigan, Ann Arbor, MI, 48109
                [b ]Translational Oncology Program, Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, 48109
                [c ]Department of Pharmacology and Therapeutics, University of Florida, FL, 32611
                [d ]Department of Pathology, University of Michigan, Ann Arbor, MI, 48109
                Author notes
                [* ]To whom correspondence may be addressed: University of Michigan, Translational Oncology Program, NCRC Building 520, Rm 1352, 1600 Huron Parkway, Ann Arbor, MI 48109-2800, Phone: 734-615-4814, elawlor@ 123456med.umich.edu , University of Florida, College of Medicine, Department of Pharmacology & Therapeutics, PO Box 100267, Gainesville, FL 32610, Phone: 352-294-5352, martensj@ 123456ufl.edu
                Article
                NIHMS635674
                10.1038/onc.2014.384
                4451446
                25435365
                f3d1f664-983f-4e70-90a5-c2531391cc67

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Oncology & Radiotherapy
                kcna5,potassium channel,kv1.5,polycomb,stress,cancer
                Oncology & Radiotherapy
                kcna5, potassium channel, kv1.5, polycomb, stress, cancer

                Comments

                Comment on this article